Rules-Based Medicine Newswire (Page 3)

Rules-Based Medicine Newswire (Page 3)

Comprehensive Real-Time News Feed for Rules-Based Medicine. (Page 3)

Results 41 - 60 of 733 in Rules-Based Medicine

  1. Myriad Genetics (MYGN) Trading Down 0.5%Read the original story w/Photo

    Sunday Mar 25 | Daily Political

    Myriad Genetics shares dropped 0.5% on Friday . The stock traded as low as $29.02 and last traded at $28.97.

    Comment?

  2. Myriad Genetics (MYGN) Downgraded by BidaskClubRead the original story w/Photo

    Saturday Mar 24 | AmericanBankingNews.com

    A number of other research analysts have also weighed in on the stock. BTIG Research set a $44.00 price target on shares of Myriad Genetics and gave the company a "buy" rating in a research note on Wednesday, February 7th.

    Comment?

  3. Guggenheim Capital LLC Trims Stake in Myriad GeneticsRead the original story w/Photo

    Saturday Mar 24 | AmericanBankingNews.com

    Guggenheim Capital LLC trimmed its position in shares of Myriad Genetics by 7.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission . The fund owned 372,103 shares of the company's stock after selling 30,773 shares during the quarter.

    Comment?

  4. Myriad Genetics (MYGN) Stock Rating Upgraded by Morgan StanleyRead the original story w/Photo

    Mar 21, 2018 | AmericanBankingNews.com

    The firm presently has a $28.00 target price on the stock. Morgan Stanley's price target would suggest a potential downside of 8.82% from the stock's current price.

    Comment?

  5. NASDAQ: MYGN Shareholder Notice: Investigation over Possible...Read the original story w/Photo

    Mar 21, 2018 | SBWire

    An investigation was announced for investors in NASDAQ: MYGN shares over potential securities laws violations by Myriad Genetics, Inc. in connection with certain financial statements. Investors who purchased shares of Myriad Genetics, Inc. , have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1 779 - 1554.

    Comment?

  6. Genetic Testing Market 2018 : Size, Share, Segmentation & Business...Read the original story w/Photo

    Mar 12, 2018 | SBWire

    MarketResearchFuture.com adds "Genetic Testing Market - 2018 Global Analysis, Growth, Trends and Opportunities Research Report forecasting to 2023" reports to its database. TRY FREE SAMPLE REPORT @ .

    Comment?

  7. Myriad Genetics, Inc. (MYGN) Position Cut by Bamco Inc. NYRead the original story w/Photo

    Mar 11, 2018 | IntersportsWire

    Bamco Inc. NY lessened its position in shares of Myriad Genetics, Inc. by 14.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 185,000 shares of the company's stock after selling 30,500 shares during the quarter.

    Comment?

  8. Myriad Genetics, Inc. (MYGN) Stake Raised by Rhumbline AdvisersRead the original story w/Photo

    Mar 9, 2018 | Daily Political

    Rhumbline Advisers lifted its stake in shares of Myriad Genetics, Inc. by 18.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 162,219 shares of the company's stock after purchasing an additional 24,839 shares during the quarter.

    Comment?

  9. Rhumbline Advisers Has $5.57 Million Position in Myriad Genetics, Inc.Read the original story w/Photo

    Mar 9, 2018 | AmericanBankingNews.com

    Rhumbline Advisers boosted its stake in shares of Myriad Genetics, Inc. by 18.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission . The firm owned 162,219 shares of the company's stock after purchasing an additional 24,839 shares during the quarter.

    Comment?

  10. Northstar Asset Management Decreased Its Mondelez International...Read the original story

    Mar 9, 2018 | Hill Country Times

    Northstar Asset Management Decreased Its Mondelez International Holding by $958,800; Stock Rose; Myriad Genetics Holder S&T Bank Cut Holding by $902,880 Northstar Asset Management Llc decreased its stake in Mondelez International by 33.6% based on its latest 2017Q3 regulatory filing with the SEC. Northstar Asset Management Llc sold 23,970 shares as the company's stock rose 7.60% with the market.

    Comment?

  11. Allianz Asset Management GmbH Has $16.66 Million Stake in Myriad Genetics, Inc.Read the original story w/Photo

    Mar 9, 2018 | IntersportsWire

    Allianz Asset Management GmbH grew its position in Myriad Genetics, Inc. by 4,202.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 485,018 shares of the company's stock after purchasing an additional 473,745 shares during the quarter.

    Comment?

  12. 57,500 Shares in Myriad Genetics, Inc. (MYGN) Purchased by Arrowstreet Capital Limited PartnershipRead the original story w/Photo

    Mar 9, 2018 | AmericanBankingNews.com

    Arrowstreet Capital Limited Partnership acquired a new position in Myriad Genetics, Inc. during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 57,500 shares of the company's stock, valued at approximately $1,975,000.

    Comment?

  13. ValuEngine Lowers Myriad Genetics (MYGN) to HoldRead the original story w/Photo

    Mar 7, 2018 | Daily Political

    A number of other equities analysts also recently weighed in on the stock. BidaskClub downgraded shares of Myriad Genetics from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, February 28th.

    Comment?

  14. $187.82 Million in Sales Expected for Myriad Genetics, Inc. (MYGN) This QuarterRead the original story w/Photo

    Mar 5, 2018 | The Breeze

    Equities analysts predict that Myriad Genetics, Inc. will post sales of $187.82 million for the current quarter, according to Zacks Investment Research . Six analysts have issued estimates for Myriad Genetics' earnings, with the highest sales estimate coming in at $189.25 million and the lowest estimate coming in at $187.00 million.

    Comment?

  15. ValuEngine Upgrades Myriad Genetics (MYGN) to BuyRead the original story w/Photo

    Mar 5, 2018 | Daily Political

    A number of other research analysts have also recently issued reports on the company. Zacks Investment Research cut Myriad Genetics from a strong-buy rating to a hold rating in a report on Friday, December 15th.

    Comment?

  16. Myriad Genetics (MYGN) Rating Increased to Buy at ValuEngineRead the original story w/Photo

    Mar 4, 2018 | IntersportsWire

    Other equities analysts have also issued research reports about the company. Morgan Stanley increased their target price on Myriad Genetics from $26.00 to $28.00 and gave the stock an underweight rating in a research note on Wednesday, February 7th.

    Comment?

  17. State of Wisconsin Investment Board Has $2.19 Million Position in Myriad Genetics, Inc.Read the original story w/Photo

    Mar 4, 2018 | AmericanBankingNews.com

    State of Wisconsin Investment Board boosted its position in shares of Myriad Genetics, Inc. by 38.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 63,800 shares of the company's stock after purchasing an additional 17,800 shares during the quarter.

    Comment?

  18. SG Americas Securities LLC Purchases 1,979 Shares of Myriad Genetics, Inc.Read the original story w/Photo

    Mar 4, 2018 | IntersportsWire

    SG Americas Securities LLC raised its position in Myriad Genetics, Inc. by 42.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 6,673 shares of the company's stock after buying an additional 1,979 shares during the quarter.

    Comment?

  19. Myriad Genetics (MYGN) Stock Rating Lowered by BidaskClubRead the original story w/Photo

    Mar 4, 2018 | IntersportsWire

    A number of other research analysts have also commented on MYGN. BTIG Research set a $44.00 price target on Myriad Genetics and gave the stock a buy rating in a report on Wednesday, February 7th.

    Comment?

  20. Credit Agricole S a Sells 99,686 Shares of Myriad Genetics, Inc.Read the original story w/Photo

    Mar 3, 2018 | AmericanBankingNews.com

    Credit Agricole S A cut its position in Myriad Genetics, Inc. by 69.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 44,726 shares of the company's stock after selling 99,686 shares during the quarter.

    Comment?